Gynecomastia: Drugs That Cause It and Drugs That Treat It

What Gynecomastia Actually Is

Gynecomastia is the benign proliferation of glandular breast tissue in males, distinct from pseudogynecomastia (fat deposition without glandular growth). It results from a relative increase in estrogen signaling compared to androgen signaling at the breast [1]. The condition affects an estimated 50 to 65% of men worldwide at some stage of life, with peaks during infancy, puberty, and older age [2].

A palpable, firm, concentric disc of tissue beneath the areola is the hallmark finding. Ultrasound or mammography can differentiate glandular tissue from adipose tissue in ambiguous cases. The Endocrine Society recommends checking serum testosterone, estradiol, LH, FSH, beta-hCG, and hepatic and thyroid function to identify treatable causes [3]. Most cases in adolescents resolve spontaneously within 6 to 24 months. In adults, identifying and discontinuing the offending drug is the single most effective first step.

Drug-induced gynecomastia accounts for roughly 10 to 25% of all cases [1]. The mechanism varies by drug class. Some medications increase estrogen production, others block androgen receptors, and still others raise prolactin or displace estrogen from sex hormone-binding globulin (SHBG). Recognizing these mechanisms matters because the treatment strategy depends on the underlying pharmacologic insult.

Drugs That Cause Gynecomastia

The list of medications associated with breast tissue enlargement in men is long. Below are the best-documented offenders, grouped by mechanism.

Antiandrogens and Hormonal Agents

Bicalutamide, flutamide, and enzalutamide block the androgen receptor directly. Gynecomastia occurs in 40 to 70% of men taking bicalutamide monotherapy for prostate cancer [4]. Flutamide carries a similar rate. GnRH agonists such as leuprolide cause gynecomastia in roughly 5 to 10% of patients by suppressing testicular testosterone production [5].

5-alpha reductase inhibitors (finasteride 1 to 5 mg, dutasteride 0.5 mg) shift the androgen-estrogen ratio by lowering dihydrotestosterone. Gynecomastia occurs in about 1 to 2% of users, though the absolute risk is low [6]. Exogenous estrogens and testosterone (through peripheral aromatization to estradiol) can both promote breast tissue growth.

Spironolactone

Spironolactone is the most frequently cited drug cause outside of oncology. It binds the androgen receptor as an antagonist, inhibits testosterone synthesis, and may increase peripheral aromatization. Incidence ranges from 4 to 10% at doses of 50 to 100 mg daily and climbs higher at 200 mg or above [7]. The effect is dose-dependent and typically reversible within months of discontinuation. Eplerenone, a selective mineralocorticoid receptor antagonist, has far less antiandrogenic activity and rarely causes gynecomastia.

Psychotropic Medications

Risperidone is the antipsychotic most strongly linked to gynecomastia, owing to its potent prolactin-elevating effect. Hyperprolactinemia suppresses GnRH, reducing testosterone and shifting the estrogen-androgen balance [8]. Other antipsychotics (haloperidol, paliperidone) also raise prolactin but to varying degrees. Selective serotonin reuptake inhibitors have rare case reports, though a clear causal mechanism is less established.

Gastrointestinal and Cardiovascular Drugs

Cimetidine, a first-generation H2 blocker, binds the androgen receptor and inhibits estradiol hydroxylation. Gynecomastia was reported in up to 4% of men taking high-dose cimetidine for Zollinger-Ellison syndrome [9]. Ranitidine and famotidine carry much lower risk. Proton pump inhibitors are not associated with gynecomastia at standard doses.

Digoxin has structural similarity to estradiol and can bind the estrogen receptor. Calcium channel blockers (particularly verapamil and nifedipine) have scattered case reports but no strong epidemiologic signal [1]. Amiodarone has been linked to gynecomastia in isolated cases.

Other Notable Agents

Ketoconazole inhibits multiple steroidogenic enzymes, lowering testosterone while increasing estrogen precursors. Methotrexate, alkylating agents (cyclophosphamide, chlorambucil), and vinca alkaloids can damage Leydig cells, reducing testosterone output [10]. Chronic alcohol use, marijuana, and anabolic steroid abuse (followed by withdrawal) round out the common non-prescription causes.

How to Evaluate Drug-Induced Gynecomastia

The first clinical question is timing. Drug-induced gynecomastia typically appears weeks to months after starting the offending medication. A focused drug history is the most cost-effective diagnostic step.

The Endocrine Society's 2019 clinical practice guideline recommends a stepwise approach: confirm true glandular tissue on exam, review the medication list, and obtain baseline labs (total testosterone, estradiol, LH, FSH, prolactin, beta-hCG, liver function, thyroid function) [3]. If labs reveal a hormonal abnormality beyond the drug effect, further imaging (testicular ultrasound, adrenal CT) may be warranted.

Dr. Glenn Braunstein, who published the most-cited review on gynecomastia in the New England Journal of Medicine, wrote: "A careful drug history will identify the cause in approximately 10 to 25 percent of cases, and discontinuation of the offending agent is the most effective initial intervention" [1]. When the causative drug cannot be stopped (for example, bicalutamide in metastatic prostate cancer), pharmacologic treatment or prophylactic radiation become the next considerations.

The tissue response matters for treatment planning. Gynecomastia that has been present for less than 12 months is more likely to be in the "proliferative" phase, where glandular tissue is actively growing and responsive to antiestrogen therapy. After 12 months, fibrosis and hyalinization dominate, and medical treatment becomes less effective [11]. This window is why early intervention matters.

Tamoxifen: The Best-Studied Treatment

Tamoxifen, a selective estrogen receptor modulator (SERM), is the most effective and best-documented pharmacologic treatment for gynecomastia. It competitively blocks estrogen receptors in breast tissue while leaving most other estrogen-dependent tissues relatively unaffected.

A retrospective series published in the Journal of Clinical Endocrinology & Metabolism reported that tamoxifen 10 to 20 mg daily produced complete regression in 78% of patients and partial regression in an additional 6% over a mean treatment period of approximately 4 months [12]. Response rates are highest when treatment begins within the first year of symptom onset.

Standard dosing is 10 mg twice daily or 20 mg once daily for 3 to 9 months. Side effects are uncommon at these doses and durations. The most frequently reported issues include mild nausea, headache, and (rarely) venous thromboembolism [12]. Long-term tamoxifen use for breast cancer prevention in women has a well-characterized risk profile, but the short courses used in gynecomastia carry substantially less cumulative risk.

For men receiving androgen deprivation therapy for prostate cancer, tamoxifen 20 mg daily has been studied as prophylaxis. A randomized trial by Fradet et al. (N=282) demonstrated that tamoxifen reduced the incidence of bicalutamide-induced gynecomastia from 73% to 10% at 12 months [13]. Dr. Yves Fradet noted that tamoxifen "was significantly more effective than anastrozole in preventing gynecomastia and breast pain during bicalutamide therapy" [13].

Raloxifene as an Alternative SERM

Raloxifene 60 mg daily is a second-line option. A prospective study by Lawrence et al. showed that raloxifene produced a partial response in approximately 50% of adolescents with persistent pubertal gynecomastia, compared to 86% for tamoxifen [14]. The study included 38 patients followed over a mean of 8 months.

Raloxifene may be preferred when tamoxifen is contraindicated (history of deep vein thrombosis in some clinical contexts) or when clinicians want to avoid tamoxifen's hypothalamic effects on the HPG axis. Raloxifene has less impact on LH and FSH elevation because its hypothalamic SERM activity profile differs [14]. Both drugs are used off-label for gynecomastia. Neither carries an FDA indication for this condition.

Aromatase Inhibitors: Less Effective Than SERMs

Aromatase inhibitors (AIs) such as anastrozole (1 mg daily) and letrozole (2.5 mg daily) block the conversion of testosterone to estradiol in peripheral tissues. The pharmacologic rationale is straightforward: reduce estrogen at its source.

Clinical results have been disappointing compared to SERMs. A double-blind, placebo-controlled trial by Plourde et al. (N=80) found that anastrozole 1 mg daily did not significantly reduce breast volume in boys with pubertal gynecomastia compared to placebo over 6 months [15]. The change from baseline in calculated breast volume was not statistically significant (P = 0.47).

In the head-to-head prophylaxis trial by Fradet et al., tamoxifen reduced gynecomastia incidence to 10% while anastrozole reduced it to only 51% (compared to 73% with placebo) [13]. This 41-percentage-point gap between the two active drugs is the strongest evidence favoring SERMs over AIs.

AIs may still have a limited role in specific clinical scenarios: men with estrogen-secreting tumors, men on exogenous testosterone with elevated estradiol, or as adjuncts when SERMs alone produce insufficient response. Letrozole has slightly more potent aromatase suppression than anastrozole and is sometimes tried when anastrozole fails, though no randomized gynecomastia-specific comparison exists between the two.

Testosterone Replacement in Hypogonadal Men

When gynecomastia occurs in the setting of documented hypogonadism (total testosterone consistently below 300 ng/dL with symptoms), testosterone replacement therapy (TRT) can paradoxically help by restoring the androgen-estrogen ratio. The key is that TRT must raise testosterone sufficiently to overcome the estrogenic signal.

There is a complication. Exogenous testosterone is itself aromatized to estradiol, meaning TRT can initially worsen gynecomastia before improving it [16]. Monitoring serum estradiol 6 to 8 weeks after initiation is standard practice. If estradiol rises above 40 to 50 pg/mL and breast tenderness develops, a low-dose AI (anastrozole 0.25 to 0.5 mg two to three times weekly) is sometimes co-prescribed to control the estrogen spike [16].

The Endocrine Society's testosterone therapy guideline recommends against routine co-administration of AIs with TRT, noting that long-term estrogen suppression in men may impair bone mineral density and lipid profiles [17]. Co-prescribing should be reserved for documented estradiol elevation with clinical symptoms.

When Surgery Becomes Necessary

Medical therapy works best within the first 12 months. Once breast tissue has undergone fibrosis, medications rarely produce meaningful regression. Subcutaneous mastectomy (often with liposuction-assisted technique) is the definitive treatment for longstanding or severe gynecomastia [18].

Surgical referral is reasonable when medical therapy has failed after 6 to 9 months, when the gynecomastia has been present for more than 2 years, when tissue is predominantly fibrotic on imaging, or when the patient has significant psychological distress. Recurrence after surgery is uncommon if the underlying hormonal driver has been addressed. Leaving the offending medication in place while performing surgery invites recurrence.

Prophylactic low-dose radiation (a single fraction of 12 to 15 Gy to the breast bud) is used in some prostate cancer centers before starting bicalutamide. A systematic review found that radiation reduced gynecomastia incidence by roughly 50%, though it was less effective than tamoxifen prophylaxis [19].

A Practical Decision Framework

The approach depends on three variables: the cause, the duration, and the severity.

If a causative drug is identified and can be stopped, discontinue it. Most cases will begin to regress within 1 to 3 months. If the drug cannot be stopped (oncology, psychiatry, heart failure), start tamoxifen 10 to 20 mg daily as the first-line pharmacologic intervention. Reassess at 3 months. If partial response, continue to 6 to 9 months. If no response at 3 months, reconsider the diagnosis and check labs again.

For pubertal gynecomastia persisting beyond 24 months, a trial of tamoxifen is reasonable before committing to surgery. For hypogonadal men, correct the testosterone deficit first and monitor estradiol closely. Reserve surgery for fibrotic, longstanding, or treatment-refractory cases.

Baseline mammography or ultrasound should be obtained in any man over 50 with unilateral, rapidly growing, or painful breast enlargement to exclude male breast cancer, which accounts for <1% of all breast cancers but presents similarly [20].